

Hojabr Kakavand

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4051674/publications.pdf>

Version: 2024-02-01

23
papers

6,150
citations

394421

19
h-index

642732

23
g-index

23
all docs

23
docs citations

23
times ranked

11797
citing authors

#	ARTICLE	IF	CITATIONS
1	Genomic Classification of Cutaneous Melanoma. <i>Cell</i> , 2015, 161, 1681-1696.	28.9	2,562
2	Whole-genome landscapes of major melanoma subtypes. <i>Nature</i> , 2017, 545, 175-180.	27.8	1,068
3	Loss of 5-Hydroxymethylcytosine Is an Epigenetic Hallmark of Melanoma. <i>Cell</i> , 2012, 150, 1135-1146.	28.9	688
4	PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1 clinical trials. <i>Pigment Cell and Melanoma Research</i> , 2015, 28, 245-253.	3.3	356
5	Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway. <i>Nature Genetics</i> , 2015, 47, 1194-1199.	21.4	221
6	Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma. <i>Clinical Cancer Research</i> , 2017, 23, 5024-5033.	7.0	192
7	Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients. <i>Modern Pathology</i> , 2017, 30, 1666-1676.	5.5	150
8	Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 10995-11000.	7.1	146
9	PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients. <i>Clinical Cancer Research</i> , 2015, 21, 3140-3148.	7.0	120
10	<i>BRAF/NRAS</i> Wild-Type Melanomas Have a High Mutation Load Correlating with Histologic and Molecular Signatures of UV Damage. <i>Clinical Cancer Research</i> , 2013, 19, 4589-4598.	7.0	115
11	Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma. <i>British Journal of Cancer</i> , 2014, 111, 292-299.	6.4	93
12	Genetic and clinico-pathologic analysis of metastatic uveal melanoma. <i>Modern Pathology</i> , 2014, 27, 175-183.	5.5	78
13	Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases. <i>Modern Pathology</i> , 2015, 28, 1535-1544.	5.5	76
14	PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors. <i>Clinical Cancer Research</i> , 2017, 23, 6054-6061.	7.0	75
15	Melanomas of unknown primary have a mutation profile consistent with cutaneous sun-exposed melanoma. <i>Pigment Cell and Melanoma Research</i> , 2013, 26, 852-860.	3.3	48
16	Comparison of whole-exome sequencing of matched fresh and formalin fixed paraffin embedded melanoma tumours: implications for clinical decision making. <i>Pathology</i> , 2016, 48, 261-266.	0.6	39
17	Expression of the class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma. <i>Modern Pathology</i> , 2015, 28, 884-894.	5.5	37
18	<i>BRAF</i> ^{V600E} and <i>NRAS</i> ^{Q61L/Q61R} mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting. <i>Histopathology</i> , 2016, 69, 680-686.	2.9	28

#	ARTICLE	IF	CITATIONS
19	Concordant BRAFV600E mutation status in primary melanomas and associated naevi: implications for mutation testing of primary melanomas. <i>Pathology</i> , 2014, 46, 193-198.	0.6	19
20	Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists. <i>Pathology</i> , 2016, 48, 194-202.	0.6	19
21	Tumour procurement, DNA extraction, coverage analysis and optimisation of mutation-detection algorithms for human melanoma genomes. <i>Pathology</i> , 2015, 47, 683-693.	0.6	9
22	Identification of new prognostic biomarkers for Stage III metastatic melanoma patients. <i>Oncolmmunology</i> , 2013, 2, e25564.	4.6	6
23	How anti-PD1 treatments are changing the management of melanoma. <i>Melanoma Management</i> , 2014, 1, 165-172.	0.5	5